NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06191744 2026-03-03
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05929222 2025-12-24
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed